STOCK TITAN
  1. Home
  2. Sec-filings
  3. TARA
  4. [SCHEDULE 13G] Protara Therapeutics, Inc. SEC Filing

[SCHEDULE 13G] Protara Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock TARA logo
Protara Therapeutics Inc

NASDAQ:TARA

TARA Rankings

#5892 Ranked by Market Cap
N/A Ranked by Dividends

TARA Latest News

Jul 1, 2025
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 1, 2025
Catalio Capital Management Raises Over $400M to Invest in Innovative Healthcare Companies in its Fourth Venture Fund
Jun 30, 2025
Protara Therapeutics Announces Addition to the Russell 3000® Index
Jun 2, 2025
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
May 13, 2025
Protara Therapeutics to Participate in Upcoming Investor Conferences

TARA Latest SEC Filings

Jul 7, 2025
[Form 4] Protara Therapeutics, Inc. Insider Trading Activity
Jun 30, 2025
[Form 4] Protara Therapeutics, Inc. Insider Trading Activity

TARA Stock Data

120.38M
37.47M
3.48%
86.65%
8.08%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK